A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

NCT04241068 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1696

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's Decision

Conditions

Alzheimer's Disease

Interventions

DRUG: Aducanumab

Sponsor

Biogen